Ideaya Biosciences Inc (IDYA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ideaya Biosciences Inc (IDYA) has a cash flow conversion efficiency ratio of 0.130x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($142.21 Million) by net assets ($1.09 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ideaya Biosciences Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Ideaya Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Ideaya Biosciences Inc (IDYA) total liabilities for a breakdown of total debt and financial obligations.
Ideaya Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ideaya Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Publishing & Media Co Ltd
SHG:601921
|
-0.030x |
|
Qingdao Rural Commercial Bank Corp Class A
SHE:002958
|
0.250x |
|
Woolworths Holdings Ltd
JSE:WHL
|
0.247x |
|
Wuxi Nce Power Co Ltd
SHG:605111
|
0.030x |
|
Data Patterns (India) Limited
NSE:DATAPATTNS
|
-0.032x |
|
Bel Fuse B Inc
NASDAQ:BELFB
|
0.057x |
|
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB
|
0.134x |
|
ABM Industries Incorporated
NYSE:ABM
|
0.075x |
Annual Cash Flow Conversion Efficiency for Ideaya Biosciences Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Ideaya Biosciences Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Ideaya Biosciences Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.06 Billion | $-247.58 Million | -0.234x | -26.00% |
| 2023-12-31 | $621.09 Million | $-115.22 Million | -0.186x | +25.63% |
| 2022-12-31 | $349.45 Million | $-87.17 Million | -0.249x | -34.85% |
| 2021-12-31 | $301.51 Million | $-55.78 Million | -0.185x | -166.13% |
| 2020-12-31 | $198.27 Million | $55.46 Million | 0.280x | +171.44% |
| 2019-12-31 | $100.40 Million | $-39.31 Million | -0.392x | -169.39% |
| 2018-12-31 | $-48.95 Million | $-27.62 Million | 0.564x | -27.35% |
| 2017-12-31 | $-15.74 Million | $-12.22 Million | 0.777x | -- |
About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methion… Read more